Saturday, June 25, 2022

What’s Going On With Eastgate Biotech Corp (OTCMKTS:ETBI)

What’s going on in Eastgate Biotech Corp (OTCMKTS:ETBI) shares is any ones guess, and any time you see a stock move 150% or more you must ask the question. I see (by looking at the technical picture in a chart below) that this is a stock that made a high volume low and turning out of triple sub penny status and are retracing losses from early April.

When a stock trades 65 million shares something is up. It goes back to the volume strategy all sub penny traders must adhere to in terms of the volume growth ramp driving prices higher. The presence of new money in the stock has been a consistent theme with many movers we write about. Be aware that you must pay attention when this volume begins to decline, because when the music stops (and it always does), shares can have unwanted downside volatility.

Eastgate Biotech Corp(OTCMKTS:ETBI) is an emerging pharmaceutical stock that produces and distributes innovative and healthy nutraceuticals based on natural therapies as well as focusing on new pharmaceutical developments. The driver revolves around its recent acquisition, OMNI Surgery and Anti-Aging Centre has appointed a new Medical Director. Dr. Ishaan Sundar has assumed the role of Medical Director effective immediately. Educated by the American Academy of Aesthetic Medicine, American Cosmetic Cellular Medicine Association, Laser Sheer Training Academy and trained in Injectable Placements, Dr. Sundar brings over 20 years of extensive practice to the OMNI state-of-the-art centre. With a distinguished career in Critical Care Medicine (ICU, CCU), Dr. Sundar will oversee medical and surgical operations at Saskatchewan’s only combined fee-for-service surgical and anti-aging centre.

OMNI Surgery and Anti-Aging Centre is an upscale facility serving an underserved market in Regina, Saskatchewan, Canada with great growth potential. It is poised to participate in the growing anti-aging market. According to Transparency Market Research, the “Global Anti-Aging Market Boosted by Baby Boomer Population nearing retirement is to be worth US$191.7 Billion by 2019.”

“We are thrilled to welcome an experienced physician like Dr. Sundar to our leadership team. His holistic approach of crafting treatment plans unique to each individual mirrors OMNI’s mission of making our patients feel comfortable and at ease, while getting the results that they want,” states Bill Abajian, Global Business Development and Licensing at EastGate and former owner of OMNI Surgery.

Find out when $ETBI stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

“OMNI Surgery brings to EastGate Biotech approximately $2 million USD in assets, a plug and play business model, with an upcoming reputation for excellence in the Anti-Aging industry,” said Anna Gluskin, CEO of EastGate. “Our longer term goal is to be able to replicate the OMNI Surgery + Anti-Aging clinics throughout up in coming markets in North America; establishing ourselves as a leader in the anti-aging market, also giving EastGate the opportunity to market and educate our clientele about our other innovative products, as a means of preventative healthcare,” concluded Gluskin.

OMNI is a fee-for-service, Surgery + Anti-Aging Centre offering plastic, orthopaedic, along with general surgical procedures. Alongside the surgical procedures, the Anti-Aging Centre is equipped with State-of-the-Art technology that work to contour, tone, and remove blemishes in order to reverse the aging process. As a Centre of Excellence in Saskatchewan, OMNI’s board-certified surgeons work to deliver high quality care mindful of patients’ needs, while helping them achieve the results they want.

EastGate Biotech Corp. (OTCMKTS:ETBI) produces and distributes innovative and healthy nutraceuticals that are based on natural therapies and absorbed naturally by the body. But the real question here is about how shares will trade over the coming weeks and any retest of the lows on higher volume would be bad, on the upside you need to retrace the decline and test .03 cents which is another big leg higher for ETBI stock.

This would be easy to track by observing the volume alone, the short term players are here, now you need to sort out the meaning of these volume clues – they translate to price so often it emerges as the most important metric to watch on any trading day. For more news on $ETBI and other fast-moving penny stocks, please subscribe to OracleDispatch.com below.

 

Related Articles

1 COMMENT

  1. As far as I know, Eastgate is in insolvency; company lost all scientists and does not pay for leased equipment. It has problems with paying hydro and patent lawyers bills and cannot support its patent applications.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
3,360FollowersFollow
19,700SubscribersSubscribe

Latest Articles